首页> 外文期刊>Therapeutic Drug Monitoring >Population pharmacokinetics of modafinil and its acid and sulfone metabolites in Chinese males.
【24h】

Population pharmacokinetics of modafinil and its acid and sulfone metabolites in Chinese males.

机译:中国男性莫达非尼及其酸和砜代谢物的群体药代动力学

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Modafinil is a psychostimulant used to treat excessive sleepiness. The aim of this study was to develop a population pharmacokinetic model of modafinil and its major metabolites in Chinese male adults and to identify covariates that predict variability in disposition. METHODS: Eighty healthy volunteer subjects were randomized to 4 oral dose groups: 3 doses of 50 mg of modafinil, 3 doses of 100 mg of modafinil, 2 doses of 200 mg of modafinil plus 1 dose of placebo, or 3 doses of placebo (each dose given 8 hourly). Blood samples were collected up to 58 hours post-first dose for plasma concentrations of modafinil and its metabolites. Pharmacokinetic data analyses were performed using noncompartmental and compartmental approaches. The population pharmacokinetic study was conducted using the nonlinear mixed-effects model software, NONMEM, and validated using the bootstrap, crossvalidation and visual predictive check approaches. RESULTS: Data were best described by a 5-compartment model: 2 compartments for modafinil (first-order absorption from gut compartment) and 1 each for modafinil acid and modafinil sulfone. A covariate analysis identified body weight as influencing volumes of the central and peripheral compartments for modafinil. All the parameters were estimated with good precision (relative standard error < 39%). The visual predictive check found that the final pharmacokinetic model adequately predicted observed concentrations of all 3 molecular species. The authors developed dosing schedules to achieve minimum trough plasma modafinil concentrations of 3 mcg/mL. CONCLUSIONS: A robust population pharmacokinetic model for modafinil and its metabolites was developed for the first time. Based on this model, individualized dosing based on weight is now possible.
机译:背景:莫达非尼是一种用于治疗过度嗜睡的精神刺激药。这项研究的目的是建立莫达非尼及其主要代谢产物在中国男性成年人中的群体药代动力学模型,并鉴定出预测性状变异的协变量。方法:将80名健康志愿者随机分为4个口服剂量组:3剂50毫克莫达非尼,3剂100毫克莫达非尼,2剂200毫克莫达非尼加1剂安慰剂或3剂安慰剂(各3剂)每小时8剂)。在首次给药后长达58小时内收集血样,以测定莫达非尼及其代谢产物的血浆浓度。使用非房室和房室方法进行药代动力学数据分析。人群药代动力学研究使用非线性混合效应模型软件NONMEM进行,并使用自举,交叉验证和视觉预测检查方法进行了验证。结果:数据最好用五室模型来描述:莫达非尼有2个隔室(从肠道隔室一级吸收),莫达非尼酸和莫达非尼砜各有1个隔室。协变量分析确定体重为莫达非尼影响中央和外周区室的体积。所有参数的估计精度都很高(相对标准误差<39%)。视觉预测检查发现最终的药代动力学模型充分预测了所有3种分子种类的观察浓度。作者制定了给药方案,以使最低谷血浆莫达非尼浓度达到3 mcg / mL。结论:首次建立了莫达非尼及其代谢物的健壮的群体药代动力学模型。基于此模型,现在可以根据重量进行个性化配量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号